Miguel Blanca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Miguel Blanca has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Maria Jose Torres
Allergy Research Group, IBIMA-Plataforma BIONAND, Instituto de Investigación Biomédica de Málaga, 29009 Malaga, Spain
10 shared publications - Jose Antonio Cornejo-Garcia
Allergy Research Group, IBIMA-Plataforma BIONAND, Instituto de Investigación Biomédica de Málaga, 29009 Malaga, Spain
9 shared publications - James Richard Perkins
Department of Molecular Biology and Biochemistry, University of Malaga, Malaga, Spain
7 shared publications - Bernard Yu-Hor Thong
Department of Rheumatology, Allergy and Immunology Tan Tock Seng Hospital Singapore Singapore
6 shared publications - Cristobalina Mayorga
Allergy Unit Hospital Regional Universitario de Málaga and Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina‐IBIMA Plataforma BIONAND Málaga Spain
6 shared publications Gabriela Canto
Infanta Leonor University Hospital , Madrid, Spain
6 shared publications
Latest Publications
- 3 June 2024
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 185 (10) , 953-963
Ibuprofen and Other Arylpropionics: The Relevance in Immediate Hypersensitivity Drug Reactions
Background: Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), is the most frequent medication to be involved in hypersensitivity drug reactions (HDRs). Other analgesic/anti-inflammatory drugs in the arylpropionic group are also relevant, albeit to a lesser extent. Ibuprofen is widely consumed by people of all ages, both on medical prescription and over the counter; moreover, it is an organic contaminant of surface waters and foods. While numerous drugs cause HDR, ibuprofen’s underlying mechanisms are more intricate and involve both specific immunological and non-immunological mediated reactions. Summary: we concentrate on immediate responses, including urticaria with or without angioedema, anaphylaxis, and angioedema, classifying reactions according to whether they are caused by single or multiple NSAIDs and based on the mechanisms at play. Both groups may experience anaphylaxis, defined as an immediate, severe systemic reaction involving at least two organs, though the frequency and severity can vary. Following this classification, more clinical manifestations can be identified. Diagnosis is partly based on a detailed clinical history, including information about ibuprofen and/or other arylpropionic derivatives involved, the interval between drug intake and symptoms onset, clinical manifestations, number of episodes, and the patient’s tolerance or response to other medications – mainly non-chemically related NSAID – both before and after reactions to ibuprofen and/or other arylpropionic drugs. A drug provocation test is frequently necessary to make a diagnosis. Key Message: Because ibuprofen is the most widely prescribed NSAID, it is reasonable to assume its role as the leading cause of HDR will only become more important.
- 3 June 2024
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 185 (10) , 953-963
Ibuprofen and Other Arylpropionics: The Relevance in Immediate Hypersensitivity Drug Reactions
Background: Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), is the most frequent medication to be involved in hypersensitivity drug reactions (HDRs). Other analgesic/anti-inflammatory drugs in the arylpropionic group are also relevant, albeit to a lesser extent. Ibuprofen is widely consumed by people of all ages, both on medical prescription and over the counter; moreover, it is an organic contaminant of surface waters and foods. While numerous drugs cause HDR, ibuprofen’s underlying mechanisms are more intricate and involve both specific immunological and non-immunological mediated reactions. Summary: we concentrate on immediate responses, including urticaria with or without angioedema, anaphylaxis, and angioedema, classifying reactions according to whether they are caused by single or multiple NSAIDs and based on the mechanisms at play. Both groups may experience anaphylaxis, defined as an immediate, severe systemic reaction involving at least two organs, though the frequency and severity can vary. Following this classification, more clinical manifestations can be identified. Diagnosis is partly based on a detailed clinical history, including information about ibuprofen and/or other arylpropionic derivatives involved, the interval between drug intake and symptoms onset, clinical manifestations, number of episodes, and the patient’s tolerance or response to other medications – mainly non-chemically related NSAID – both before and after reactions to ibuprofen and/or other arylpropionic drugs. A drug provocation test is frequently necessary to make a diagnosis. Key Message: Because ibuprofen is the most widely prescribed NSAID, it is reasonable to assume its role as the leading cause of HDR will only become more important.
- 1 August 2021
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 21 (4) , 317-319
Editorial: Advances in drug hypersensitivity reactions
- 1 August 2021
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 21 (4) , 317-319
Editorial: Advances in drug hypersensitivity reactions
- 1 August 2020
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 20 (4) , 331-332
Editorial: Advances in hypersensitivity drug reactions
- 1 August 2020
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 20 (4) , 331-332
Editorial: Advances in hypersensitivity drug reactions
- Open Access
- 1 August 2019
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 12, 217-233
NSAID-induced reactions: classification, prevalence, impact, and management strategies
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the leading cause of hypersensitivity drug reactions. The different chemical structures, cyclooxygenase 1 (COX-1) and/or COX-2 inhibitors, are taken at all ages and some can be easily obtained over the counter. Vasoactive inflammatory mediators like histamine and leukotriene metabolites can produce local/systemic effects. Responders can be selective (SR), IgE or T-cell mediated, or cross-intolerant (CI). Inhibition of the COX pathway is the common mechanism in CI, with the skin being the most frequent organ involved, followed by the lung and/or the nose. An important number of cases have skin and respiratory involvement, with systemic manifestations ranging from mild to severe anaphylaxis. Among SR, this is the most frequent entity, often being severe. Recent years have seen an increase in reactions involving the skin, with many cases having urticaria and/or angioedema in the absence of chronic urticaria. Aspirin, the classical drug involved, has now been replaced by other NSAIDs, with ibuprofen being the universal culprit. For CI, no in vivo/in vitro diagnostic methods exist and controlled administration is the only option unless the cases evaluated report repetitive and consistent episodes with different NSAIDs. In SR, skin testing (patch and intradermal) with 24-48 reading can be useful, mainly for delayed T-cell responses. Acetyl salicylic acid (ASA) is the test drug to establish the diagnosis and confirm/exclude CI by controlled administration. Desensitization to ASA has been extensively used in respiratory cases though it can also be applied in those cases where it is required.
- 1 August 2019
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 12, 217-233
Open AccessNSAID-induced reactions: classification, prevalence, impact, and management strategies
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the leading cause of hypersensitivity drug reactions. The different chemical structures, cyclooxygenase 1 (COX-1) and/or COX-2 inhibitors, are taken at all ages and some can be easily obtained over the counter. Vasoactive inflammatory mediators like histamine and leukotriene metabolites can produce local/systemic effects. Responders can be selective (SR), IgE or T-cell mediated, or cross-intolerant (CI). Inhibition of the COX pathway is the common mechanism in CI, with the skin being the most frequent organ involved, followed by the lung and/or the nose. An important number of cases have skin and respiratory involvement, with systemic manifestations ranging from mild to severe anaphylaxis. Among SR, this is the most frequent entity, often being severe. Recent years have seen an increase in reactions involving the skin, with many cases having urticaria and/or angioedema in the absence of chronic urticaria. Aspirin, the classical drug involved, has now been replaced by other NSAIDs, with ibuprofen being the universal culprit. For CI, no in vivo/in vitro diagnostic methods exist and controlled administration is the only option unless the cases evaluated report repetitive and consistent episodes with different NSAIDs. In SR, skin testing (patch and intradermal) with 24-48 reading can be useful, mainly for delayed T-cell responses. Acetyl salicylic acid (ASA) is the test drug to establish the diagnosis and confirm/exclude CI by controlled administration. Desensitization to ASA has been extensively used in respiratory cases though it can also be applied in those cases where it is required.
- 1 August 2019
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 19 (4) , 263-265
Editorial: Advances in drug hypersensitivity reactions
- 1 August 2019
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 19 (4) , 263-265
Editorial: Advances in drug hypersensitivity reactions
- 3 June 2019
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 15 (7) , 707-721
Allergic reactions to penicillins and cephalosporins: diagnosis, assessment of cross-reactivity and management
Introduction: Beta-lactams (BL) are the main cause of allergic drug reactions mediated by specific immunological mechanisms. Reactions can be IgE or effector T-cell mediated. The new antigenic determinants are recognized by the immunological system in the context of the common beta-lactam structure or the specific differences in the side chains of the antibiotics of this family plus the protein carrier. Areas covered: We have reviewed the recent clinical literature concerning new clinical entities, the progress in diagnosis including the difficulties for in in vivo and or in vitro testing as well as the new algorithms proposed for delabelling subjects classified as allergic to beta-lactams, and recommendations for desensitization procedures. Expert opinion: The knowledge gained over the last years on beta-lactam hypersensitivity has enabled a better understanding and management of cases with allergic reactions to beta-lactams.
- 3 June 2019
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 15 (7) , 707-721
Allergic reactions to penicillins and cephalosporins: diagnosis, assessment of cross-reactivity and management
Introduction: Beta-lactams (BL) are the main cause of allergic drug reactions mediated by specific immunological mechanisms. Reactions can be IgE or effector T-cell mediated. The new antigenic determinants are recognized by the immunological system in the context of the common beta-lactam structure or the specific differences in the side chains of the antibiotics of this family plus the protein carrier. Areas covered: We have reviewed the recent clinical literature concerning new clinical entities, the progress in diagnosis including the difficulties for in in vivo and or in vitro testing as well as the new algorithms proposed for delabelling subjects classified as allergic to beta-lactams, and recommendations for desensitization procedures. Expert opinion: The knowledge gained over the last years on beta-lactam hypersensitivity has enabled a better understanding and management of cases with allergic reactions to beta-lactams.
- 1 August 2018
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 18 (4) , 281-283
Advances in hypersensitivity drug reactions
- 1 August 2018
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 18 (4) , 281-283
Advances in hypersensitivity drug reactions
- 1 August 2017
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 17 (4)
Editorial introductions
- 1 August 2017
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 17 (4)
Editorial introductions
- 1 August 2017
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 17 (4) , 239-240
Drug allergy/hypersensitivity in adults and children
- 1 August 2017
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 17 (4) , 239-240
Drug allergy/hypersensitivity in adults and children
- 1 August 2016
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 16 (4) , 297-299
Advances in hypersensitivity drug reactions
- 1 August 2016
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 16 (4) , 297-299
Advances in hypersensitivity drug reactions